Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-01-10

AUTHORS

Hiroaki Ueno, Hiroko Nakazato, Emi Ebihara, Kenji Noma, Takahisa Kawano, Kazuhiro Nagamine, Hideyuki Sakoda, Masamitsu Nakazato

ABSTRACT

IntroductionIpragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as to investigate the glucose-lowering mechanisms of ipragliflozin.MethodsNine Japanese patients with obesity and type 2 diabetes mellitus were treated with ipragliflozin (50 mg/day) for 12 weeks. The postprandial profiles of glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active glucose-dependent insulinotropic polypeptide (GIP), ghrelin, and des-acyl ghrelin were measured before and 12 weeks after ipragliflozin treatment.ResultsBody weight, body fat mass, systolic blood pressure, and HbA1c and serum uric acid levels were significantly decreased after the treatment. Postprandial glucose and insulin levels were also significantly decreased. Postprandial glucagon increased both before and after ipragliflozin treatment; however, the increment tended to be smaller after treatment. Active GLP-1, active GIP, ghrelin, and des-acyl ghrelin did not change after treatment.ConclusionIpragliflozin improved glycemic control by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement. Although this was a short-term study with a small sample size, ipragliflozin may offer benefits for patients with obesity and type 2 diabetes mellitus.Trial RegistrationUniversity Hospital Medical Information Network (UMIN No. 000017195). More... »

PAGES

403-411

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8

DOI

http://dx.doi.org/10.1007/s13300-018-0366-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100290978

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29322485


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueno", 
        "givenName": "Hiroaki", 
        "id": "sg:person.011104371372.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011104371372.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakazato", 
        "givenName": "Hiroko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ebihara", 
        "givenName": "Emi", 
        "id": "sg:person.016011371614.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016011371614.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Noma Naika Clinic, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Noma Naika Clinic, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noma", 
        "givenName": "Kenji", 
        "id": "sg:person.0736512042.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736512042.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kawano Naika Clinic, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Kawano Naika Clinic, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawano", 
        "givenName": "Takahisa", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagamine", 
        "givenName": "Kazuhiro", 
        "id": "sg:person.0617541045.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617541045.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakoda", 
        "givenName": "Hideyuki", 
        "id": "sg:person.0774327434.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774327434.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakazato", 
        "givenName": "Masamitsu", 
        "id": "sg:person.0725136110.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725136110.34"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-014-0089-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005793567", 
          "https://doi.org/10.1007/s13300-014-0089-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-014-3283-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031625562", 
          "https://doi.org/10.1007/s00125-014-3283-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40268-016-0137-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007120806", 
          "https://doi.org/10.1007/s40268-016-0137-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-016-0211-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017299918", 
          "https://doi.org/10.1007/s13300-016-0211-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-017-0277-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090744326", 
          "https://doi.org/10.1007/s13300-017-0277-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-01-10", 
    "datePublishedReg": "2018-01-10", 
    "description": "IntroductionIpragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as to investigate the glucose-lowering mechanisms of ipragliflozin.MethodsNine Japanese patients with obesity and type 2 diabetes mellitus were treated with ipragliflozin (50\u00a0mg/day) for 12\u00a0weeks. The postprandial profiles of glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active glucose-dependent insulinotropic polypeptide (GIP), ghrelin, and des-acyl ghrelin were measured before and 12\u00a0weeks after ipragliflozin treatment.ResultsBody weight, body fat mass, systolic blood pressure, and HbA1c and serum uric acid levels were significantly decreased after the treatment. Postprandial glucose and insulin levels were also significantly decreased. Postprandial glucagon increased both before and after ipragliflozin treatment; however, the increment tended to be smaller after treatment. Active GLP-1, active GIP, ghrelin, and des-acyl ghrelin did not change after treatment.ConclusionIpragliflozin improved glycemic control by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement. Although this was a short-term study with a small sample size, ipragliflozin may offer benefits for patients with obesity and type 2 diabetes mellitus.Trial RegistrationUniversity Hospital Medical Information Network (UMIN No. 000017195).", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-018-0366-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "glucagon-like peptide-1", 
      "glucose-dependent insulinotropic polypeptide", 
      "active glucose-dependent insulinotropic polypeptide", 
      "type 2 diabetes mellitus", 
      "sodium-glucose cotransporter 2", 
      "effect of ipragliflozin", 
      "des-acyl ghrelin", 
      "ipragliflozin treatment", 
      "diabetes mellitus", 
      "active glucagon-like peptide-1", 
      "serum uric acid levels", 
      "gastrointestinal peptide responses", 
      "glucose-lowering mechanisms", 
      "inappropriate glucagon secretion", 
      "postprandial insulin requirement", 
      "systolic blood pressure", 
      "active GLP-1", 
      "meal tolerance test", 
      "body fat mass", 
      "uric acid levels", 
      "postprandial glucose metabolism", 
      "novel antidiabetic drugs", 
      "Medical Information Network", 
      "postprandial glucagon", 
      "insulin requirements", 
      "ResultsBody weight", 
      "blood pressure", 
      "glycemic control", 
      "postprandial glucose", 
      "glucagon secretion", 
      "insulin levels", 
      "gut peptides", 
      "tolerance test", 
      "insulinotropic polypeptide", 
      "Japanese patients", 
      "fat mass", 
      "cotransporter 2", 
      "postprandial profiles", 
      "antidiabetic drugs", 
      "ipragliflozin", 
      "peptide-1", 
      "short-term studies", 
      "glucose metabolism", 
      "body weight", 
      "peptide response", 
      "ghrelin", 
      "type 2", 
      "pilot study", 
      "small sample size", 
      "acid levels", 
      "glucagon", 
      "mellitus", 
      "obesity", 
      "treatment", 
      "patients", 
      "insulin", 
      "weeks", 
      "glucose", 
      "sample size", 
      "HbA1c", 
      "secretion", 
      "drugs", 
      "study", 
      "levels", 
      "weight", 
      "metabolism", 
      "effect", 
      "aim", 
      "peptides", 
      "response", 
      "control", 
      "benefits", 
      "test", 
      "profile", 
      "pressure", 
      "mechanism", 
      "polypeptide", 
      "mass", 
      "increment", 
      "size", 
      "information networks", 
      "requirements", 
      "network"
    ], 
    "name": "Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study", 
    "pagination": "403-411", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100290978"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-018-0366-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29322485"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-018-0366-8", 
      "https://app.dimensions.ai/details/publication/pub.1100290978"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_787.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-018-0366-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8'


 

This table displays all metadata directly associated to this object as RDF triples.

216 TRIPLES      21 PREDICATES      113 URIs      100 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-018-0366-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4af19fdd1b57472bae2d1e6dd9eb25b5
4 schema:citation sg:pub.10.1007/s00125-014-3283-z
5 sg:pub.10.1007/s13300-014-0089-4
6 sg:pub.10.1007/s13300-016-0211-x
7 sg:pub.10.1007/s13300-017-0277-0
8 sg:pub.10.1007/s40268-016-0137-9
9 schema:datePublished 2018-01-10
10 schema:datePublishedReg 2018-01-10
11 schema:description IntroductionIpragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as to investigate the glucose-lowering mechanisms of ipragliflozin.MethodsNine Japanese patients with obesity and type 2 diabetes mellitus were treated with ipragliflozin (50 mg/day) for 12 weeks. The postprandial profiles of glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active glucose-dependent insulinotropic polypeptide (GIP), ghrelin, and des-acyl ghrelin were measured before and 12 weeks after ipragliflozin treatment.ResultsBody weight, body fat mass, systolic blood pressure, and HbA1c and serum uric acid levels were significantly decreased after the treatment. Postprandial glucose and insulin levels were also significantly decreased. Postprandial glucagon increased both before and after ipragliflozin treatment; however, the increment tended to be smaller after treatment. Active GLP-1, active GIP, ghrelin, and des-acyl ghrelin did not change after treatment.ConclusionIpragliflozin improved glycemic control by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement. Although this was a short-term study with a small sample size, ipragliflozin may offer benefits for patients with obesity and type 2 diabetes mellitus.Trial RegistrationUniversity Hospital Medical Information Network (UMIN No. 000017195).
12 schema:genre article
13 schema:isAccessibleForFree true
14 schema:isPartOf N567fd3ff36ab4d189209e006a1b7e761
15 Ne586c931454c403a8f9f07733010ca07
16 sg:journal.1044057
17 schema:keywords HbA1c
18 Japanese patients
19 Medical Information Network
20 ResultsBody weight
21 acid levels
22 active GLP-1
23 active glucagon-like peptide-1
24 active glucose-dependent insulinotropic polypeptide
25 aim
26 antidiabetic drugs
27 benefits
28 blood pressure
29 body fat mass
30 body weight
31 control
32 cotransporter 2
33 des-acyl ghrelin
34 diabetes mellitus
35 drugs
36 effect
37 effect of ipragliflozin
38 fat mass
39 gastrointestinal peptide responses
40 ghrelin
41 glucagon
42 glucagon secretion
43 glucagon-like peptide-1
44 glucose
45 glucose metabolism
46 glucose-dependent insulinotropic polypeptide
47 glucose-lowering mechanisms
48 glycemic control
49 gut peptides
50 inappropriate glucagon secretion
51 increment
52 information networks
53 insulin
54 insulin levels
55 insulin requirements
56 insulinotropic polypeptide
57 ipragliflozin
58 ipragliflozin treatment
59 levels
60 mass
61 meal tolerance test
62 mechanism
63 mellitus
64 metabolism
65 network
66 novel antidiabetic drugs
67 obesity
68 patients
69 peptide response
70 peptide-1
71 peptides
72 pilot study
73 polypeptide
74 postprandial glucagon
75 postprandial glucose
76 postprandial glucose metabolism
77 postprandial insulin requirement
78 postprandial profiles
79 pressure
80 profile
81 requirements
82 response
83 sample size
84 secretion
85 serum uric acid levels
86 short-term studies
87 size
88 small sample size
89 sodium-glucose cotransporter 2
90 study
91 systolic blood pressure
92 test
93 tolerance test
94 treatment
95 type 2
96 type 2 diabetes mellitus
97 uric acid levels
98 weeks
99 weight
100 schema:name Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
101 schema:pagination 403-411
102 schema:productId N29396e404bbf426587b9d3e512b42bd6
103 N3bc3f3d556184f58981862ae696de110
104 N7ff1195da17c404480592511b32a0af1
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100290978
106 https://doi.org/10.1007/s13300-018-0366-8
107 schema:sdDatePublished 2022-10-01T06:44
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher N7a7cbd13002c4b77a62830c8636bd893
110 schema:url https://doi.org/10.1007/s13300-018-0366-8
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N074277e2ab5d4cc7af4e0492f11d0e24 rdf:first sg:person.0736512042.97
115 rdf:rest N5c0e5a932fc74cb5ad9c6a8de63af54a
116 N29396e404bbf426587b9d3e512b42bd6 schema:name dimensions_id
117 schema:value pub.1100290978
118 rdf:type schema:PropertyValue
119 N3578e5ca9c204dd2828b4c4e6d365b28 schema:affiliation grid-institutes:grid.410849.0
120 schema:familyName Nakazato
121 schema:givenName Hiroko
122 rdf:type schema:Person
123 N3bc3f3d556184f58981862ae696de110 schema:name doi
124 schema:value 10.1007/s13300-018-0366-8
125 rdf:type schema:PropertyValue
126 N3c3e91856ef14046b71010c3bdc08c42 rdf:first N3578e5ca9c204dd2828b4c4e6d365b28
127 rdf:rest N69ae3a77e5884b9a89301fc3952721a1
128 N46ad0fb01bbc4f17b42fa713b16c8c6e rdf:first sg:person.0617541045.47
129 rdf:rest N7595cf5efe3d4819b741906fec46f72a
130 N4af19fdd1b57472bae2d1e6dd9eb25b5 rdf:first sg:person.011104371372.49
131 rdf:rest N3c3e91856ef14046b71010c3bdc08c42
132 N567fd3ff36ab4d189209e006a1b7e761 schema:volumeNumber 9
133 rdf:type schema:PublicationVolume
134 N5c0e5a932fc74cb5ad9c6a8de63af54a rdf:first N703459ba7c9a4e41ae8a04bfbb609cd3
135 rdf:rest N46ad0fb01bbc4f17b42fa713b16c8c6e
136 N69ae3a77e5884b9a89301fc3952721a1 rdf:first sg:person.016011371614.52
137 rdf:rest N074277e2ab5d4cc7af4e0492f11d0e24
138 N703459ba7c9a4e41ae8a04bfbb609cd3 schema:affiliation grid-institutes:None
139 schema:familyName Kawano
140 schema:givenName Takahisa
141 rdf:type schema:Person
142 N75497b7c8f5c4afdbfacbd35af438fe9 rdf:first sg:person.0725136110.34
143 rdf:rest rdf:nil
144 N7595cf5efe3d4819b741906fec46f72a rdf:first sg:person.0774327434.28
145 rdf:rest N75497b7c8f5c4afdbfacbd35af438fe9
146 N7a7cbd13002c4b77a62830c8636bd893 schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 N7ff1195da17c404480592511b32a0af1 schema:name pubmed_id
149 schema:value 29322485
150 rdf:type schema:PropertyValue
151 Ne586c931454c403a8f9f07733010ca07 schema:issueNumber 1
152 rdf:type schema:PublicationIssue
153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical and Health Sciences
155 rdf:type schema:DefinedTerm
156 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
157 schema:name Clinical Sciences
158 rdf:type schema:DefinedTerm
159 sg:journal.1044057 schema:issn 1869-6953
160 1869-6961
161 schema:name Diabetes Therapy
162 schema:publisher Springer Nature
163 rdf:type schema:Periodical
164 sg:person.011104371372.49 schema:affiliation grid-institutes:grid.410849.0
165 schema:familyName Ueno
166 schema:givenName Hiroaki
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011104371372.49
168 rdf:type schema:Person
169 sg:person.016011371614.52 schema:affiliation grid-institutes:grid.410849.0
170 schema:familyName Ebihara
171 schema:givenName Emi
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016011371614.52
173 rdf:type schema:Person
174 sg:person.0617541045.47 schema:affiliation grid-institutes:grid.410849.0
175 schema:familyName Nagamine
176 schema:givenName Kazuhiro
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617541045.47
178 rdf:type schema:Person
179 sg:person.0725136110.34 schema:affiliation grid-institutes:grid.410849.0
180 schema:familyName Nakazato
181 schema:givenName Masamitsu
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725136110.34
183 rdf:type schema:Person
184 sg:person.0736512042.97 schema:affiliation grid-institutes:None
185 schema:familyName Noma
186 schema:givenName Kenji
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736512042.97
188 rdf:type schema:Person
189 sg:person.0774327434.28 schema:affiliation grid-institutes:grid.410849.0
190 schema:familyName Sakoda
191 schema:givenName Hideyuki
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774327434.28
193 rdf:type schema:Person
194 sg:pub.10.1007/s00125-014-3283-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1031625562
195 https://doi.org/10.1007/s00125-014-3283-z
196 rdf:type schema:CreativeWork
197 sg:pub.10.1007/s13300-014-0089-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005793567
198 https://doi.org/10.1007/s13300-014-0089-4
199 rdf:type schema:CreativeWork
200 sg:pub.10.1007/s13300-016-0211-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017299918
201 https://doi.org/10.1007/s13300-016-0211-x
202 rdf:type schema:CreativeWork
203 sg:pub.10.1007/s13300-017-0277-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090744326
204 https://doi.org/10.1007/s13300-017-0277-0
205 rdf:type schema:CreativeWork
206 sg:pub.10.1007/s40268-016-0137-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007120806
207 https://doi.org/10.1007/s40268-016-0137-9
208 rdf:type schema:CreativeWork
209 grid-institutes:None schema:alternateName Kawano Naika Clinic, Miyazaki, Japan
210 Noma Naika Clinic, Miyazaki, Japan
211 schema:name Kawano Naika Clinic, Miyazaki, Japan
212 Noma Naika Clinic, Miyazaki, Japan
213 rdf:type schema:Organization
214 grid-institutes:grid.410849.0 schema:alternateName Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
215 schema:name Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
216 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...